Trial · NCT02203578
Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
NCT02203578, Not applicable, Terminated, Rutgers, The State University of New Jersey; results first posted 2017-03-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease. Trials, record NCT02203578. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02203578
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
- NCT number
- NCT02203578
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 1 participants, actual
- Lead sponsor
- Rutgers, The State University of New Jersey
- Conditions
- Graft Versus Host Disease
- Interventions
- romidepsin, laboratory biomarker analysis
- First posted
- 2014-07-30
- Last updated
- 2017-03-30
- Results first posted
- 2017-03-30
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of aGVHD | At 28 days after initiation of romidepsin | |
| Primary | Incidence of cGVHD | At 1 month after initiation of romidepsin | |
| Primary | Incidence of cGVHD | At 3 months after initiation of romidepsin | |
| Primary | Incidence of cGVHD | At 6 months after initiation of romidepsin | |
| Primary | Incidence of cGVHD | At 9 months after initiation of romidepsin | |
| Primary | Incidence of cGVHD | At 12 months after initiation of romidepsin | |
| Secondary | Total Duration of Immunosuppressive Therapy | Up to 12 months after initiation of romidepsin | |
| Secondary | Rate of Documented Infection | Up to 12 months after initiation of romidepsin | |
| Secondary | T Cell Kinetics - Reconstitution | Up to 12 months after initiation of romidepsin |
Source ClinicalTrials.gov
Outcomes9
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of aGVHD | At 28 days after initiation of romidepsin | Study was terminated early due to slow accrual and insufficient data was collected to assess this outcome measure. | ||
| PRIMARY | Incidence of cGVHD | At 1 month after initiation of romidepsin | Study was terminated early due to slow accrual and insufficient data was collected to assess this outcome measure. | ||
| PRIMARY | Incidence of cGVHD | At 3 months after initiation of romidepsin | Study was terminated early due to slow accrual and insufficient data was collected to assess this outcome measure. | ||
| PRIMARY | Incidence of cGVHD | At 6 months after initiation of romidepsin | Study was terminated early due to slow accrual and insufficient data was collected to assess this outcome measure. | ||
| PRIMARY | Incidence of cGVHD | At 9 months after initiation of romidepsin | Study was terminated early due to slow accrual and insufficient data was collected to assess this outcome measure. | ||
| PRIMARY | Incidence of cGVHD | At 12 months after initiation of romidepsin | Study was terminated early due to slow accrual and insufficient data was collected to assess this outcome measure. | ||
| SECONDARY | Total Duration of Immunosuppressive Therapy | Up to 12 months after initiation of romidepsin | Study was terminated early due to slow accrual and insufficient data was collected to assess this outcome measure. | ||
| SECONDARY | Rate of Documented Infection | Up to 12 months after initiation of romidepsin | Study was terminated early due to slow accrual and insufficient data was collected to assess this outcome measure. | ||
| SECONDARY | T Cell Kinetics - Reconstitution | Up to 12 months after initiation of romidepsin | Study was terminated early due to slow accrual and insufficient data was collected to assess this outcome measure. |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of aGVHD | Supportive Care (Romidepsin) | 0 | |||
| Incidence of cGVHD | Supportive Care (Romidepsin) | 0 | |||
| Incidence of cGVHD | Supportive Care (Romidepsin) | 0 | |||
| Incidence of cGVHD | Supportive Care (Romidepsin) | 0 | |||
| Incidence of cGVHD | Supportive Care (Romidepsin) | 0 | |||
| Incidence of cGVHD | Supportive Care (Romidepsin) | 0 | |||
| Total Duration of Immunosuppressive Therapy | Supportive Care (Romidepsin) | 0 | |||
| Rate of Documented Infection | Supportive Care (Romidepsin) | 0 | |||
| T Cell Kinetics - Reconstitution | Supportive Care (Romidepsin) | 0 |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Supportive Care (Romidepsin) | 1 | |
| Overall Study | COMPLETED | Supportive Care (Romidepsin) | 1 | |
| Overall Study | NOT COMPLETED | Supportive Care (Romidepsin) | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Supportive Care (Romidepsin) | 1 | 1 | 1 |
| serious | Endocarditis infective | Infections and infestations | Supportive Care (Romidepsin) | 1 | 1 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Supportive Care (Romidepsin) | 0 | 1 |
| Total, other adverse events | Supportive Care (Romidepsin) | 1 | 1 |
| Total, serious adverse events | Supportive Care (Romidepsin) | 1 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA072720 | Cancer Center Support Grant | LIBUTTI, STEVEN K. | RUTGERS BIOMEDICAL AND HEALTH SCIENCES | NATIONAL CANCER INSTITUTE | 1997 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02203578
GET https://conductscience.org/api/trials/v1/NCT02203578/registered